{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 458637684
| type              = mab
| image             = 
| alt               = 
| mab_type          = mab
| source            = u
| target            = [[GM-CSF receptor]] alpha chain
| tradename         =  
| Drugs.com         =
| MedlinePlus       =
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      = <!-- A / B            / C / D / X -->
| pregnancy_category=  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status      = 
| routes_of_administration = 
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         = 
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number        = 1085337-57-0
| ATC_prefix        = none
| ATC_suffix        = 
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 1158JD1P9A
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| PubChem           = 
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank          = 
| IUPHAR_ligand = 7785 | C=6706 | H=10438 | N=1762 | O=2104 | S=54
| molecular_weight = 143.2 kg/mol
}}

'''Mavrilimumab''' is a human monoclonal antibody<ref>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Mavrilimumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/mavrilimumab.pdf}}</ref> that inhibits human [[granulocyte macrophage colony-stimulating factor receptor]] (GM-CSF-R).<ref name=phaseI>{{cite journal|pmc=3147227|title=Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study|author1=Gerd R Burmester |author2=Eugen Feist |author3=Matthew A Sleeman |author4=Bing Wang |author5=Barbara White |author6=Fabio Magrini |journal=Ann. Rheum. Dis.|volume=70|issue=9|pages=1542–1549|date=1 September 2011 |doi=10.1136/ard.2010.146225|pmid=21613310}}</ref>

Mavrilimumab was discovered as CAM-3001 by [[Cambridge Antibody Technology]] and is being developed by [[MedImmune]], Inc.<ref>{{cite web|url=http://www.ama-assn.org/resources/doc/usan/mavrilimumab.pdf |title=Archived copy |accessdate=2011-09-08 |deadurl=yes |archiveurl=https://web.archive.org/web/20120928202943/http://www.ama-assn.org/resources/doc/usan/mavrilimumab.pdf |archivedate=2012-09-28 |df= }}</ref> as an [[investigational drug]] for the treatment of [[rheumatoid arthritis]] 

Mavrilimumab has been studied in a [[phase 1 clinical trial|phase 1]] dose-ranging trial<ref name=phaseI/> and a [[phase 2 clinical trial|phase 2a clinical trial]], both sponsored by Medimmune.<ref name=phaseII>{{cite journal|pmc=3756523|title=Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis |journal=Ann Rheum Dis.|author1=Gerd R Burmester |author2=Michael E Weinblatt |author3=Iain B McInnes |author4=Duncan Porter |author5=Olga Barbarash |author6=Mykola Vatutin |author7=Istvan Szombati |author8=Ehsanollah Esfandiari |author9=Matthew A Sleeman |author10=Christopher D Kane |author11=Guy Cavet |author12=Bing Wang |author13=Alex Godwood |author14=Fabio Magrini |author15=the EARTH Study Group  |last-author-amp=yes |volume=72|issue=9|pages=1445–1452|doi=10.1136/annrheumdis-2012-202450 |pmid=23234647 |year=2013}}</ref> The phase 2a trial, which studied mavrilimumab doses of up to 100&nbsp;mg, reported that 55.7% of subjects met the primary endpoint of a ≥1.2 decrease from baseline in disease activity scores at week 12 (vs. only 34.7% of placebo subjects).<ref name=phaseII/> 

As of 2013, two further clinical studies were reported to be underway in rheumatoid arthritis patients to investigate these effects further.<ref>{{cite journal|url=|title=Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis|author1=Manuela Di Franco |author2=Maria Chiara Gerardi |author3=Bruno Lucchino |author4=Fabrizio Conti  |last-author-amp=yes |journal=Core Evidence|volume=9|pages=41–48|date=12 March 2014|doi=10.2147/CE.S39770|PMC=3958547 |pmid=24648832}}</ref>

In early 2017 the phase IIb study was reported to be showing promising results.<ref>[http://www.medpagetoday.com/mastery-of-medicine/rheumatology-mastery-in-ra/63286 Agent that Targets GM-CSF Shows Promise in RA - Novel monoclonal antibody was rapidly effective in mild-to-moderate disease. Feb 2017]</ref>

==References==
<references/>

{{Monoclonals for immune system}}
{{Cytokine receptor modulators}}

[[Category:Monoclonal antibodies]]

{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}